Develop therapies for liver diseases like primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 120× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $31.1M a year. A small number, but proof the product has real buyers.
There is $394.3M in the vault; even if every debt were paid off, $279.8M would remain.
A loss of $105.4M against $31.1M in annual sales.
Over the last 12 months, executives reported 226 sells against just 74 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.